INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES

• Advancing Off-The-Shelf CRISPR CAR-T Therapies Into The Community Setting With Caribou Biosciences' Rachel Haurwitz

  On episode 120 of Cell & Gene: The Podcast, Host Erin Harris is joined by Rachel Haurwitz, CEO of Caribou Biosciences, to discuss the company’s progress in developing CRISPR-edited, off-the-shelf CAR-T therapies for hematologic malignancies.

• ARM's Tim Hunt On Expanding Patient Access, Smarter Regulation, And A More Sustainable Market In 2026

  ARM's Tim Hunt outlines how smarter regulation, evolving payment models, and global competition are reshaping CGT into a more accessible and commercially sustainable industry.

• Increase Agility By Integrating Drug Substance And Drug Product

  Biopharma success depends on agility. Move efficiently from discovery to delivery by co-locating drug substance and drug product operations, reducing transfer risks and accelerating your timeline

• Why Flexible, Collaborative Distribution Partners Matter For CGTs

  Learn how collaborative distribution models manage reimbursement hurdles and complex delivery requirements to ensure patient access and long-term commercial success.

• The Editors' Roundtable: A 2025 Retrospective of the Life Sciences Industry

  We’re sharing this episode on Cell & Gene: The Podcast because Better Biopharma is a sister podcast within the Life Science Connect family. This conversation speaks directly to the challenges and opportunities our Cell & Gene: The Podcast audience is navigating right now.

• Global Shifts And Strategic Resilience Will Shape CGT In 2026

  Dr. Miguel Forte, CEO of Kiji Therapeutics and President of ISCT, and Ali Pashazadeh, Founder of Treehill Partners share why CGT developers are now navigating a landscape defined not only by technological innovation but also by geography, regulatory agility, and investment dynamics.

• The Need For Adaptive Distribution Partners For Cell And Gene Therapies

  Optimize your commercial strategy by exploring how adaptive distribution models navigate reimbursement challenges and improve patient access. Partner early to align workflows and ensure operational success.

• Developing Itvisma for Broad-Range Treatment of SMA with Novartis' Dr. Norman Putzki

  In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA).

• CSL's HEMGENIX Shows Durable Benefit, A New Future For Gene Therapy in Hemophilia B

  CSL's Dr. Deborah Long and Diego Sacristan highlight HEMGENIX's five-year Phase 3 data as a watershed for hemophilia B gene therapy.

• End-To-End Services: Discovery To Commercialization

  Comprehensive global services accelerate biologics and cell therapy development, offering discovery, GMP manufacturing, and advanced platforms for efficient preclinical, clinical, and commercial stages.